$5.930
-0.040 (-0.67%)收盤時
- High
- 5.980
- Open
- 5.910
- VWAP
- 5.93
- Vol
- 466.63K
- Mkt Cap
- —
- Low
- 5.870
- Amount
- 2.77M
- EV/EBITDA, TTM
- -36.37
Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states.
AI analysis of STLN (STLN)
sellStarling Oncology, Inc. is not a good buy right now due to its negative fundamentals and recent performance. The current price is $6.17, and the forward P/E ratio is 0, indicating no expected earnings growth. Additionally, the stock has seen a 5-day change of -4.56%, suggesting a downward trend. The primary risk is the negative P/E ratio of -17.80, which indicates the company is currently unprofitable.
估值指標
STLN FAQ — answered by Alphio AI
Starling Oncology, Inc. is not a good buy right now due to its negative fundamentals and recent performance. The current price is $6.17, and the forward P/E ratio is 0, indicating no expected earnings growth. Additionally, the stock has seen a 5-day change of -4.56%, suggesting a downward trend. The primary risk is the negative P/E ratio of -17.80, which indicates the company is currently unprofitable.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。